Abbvie ((ABBV)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie recently completed a Phase 1 clinical study titled ‘A Phase 1, Multi-center, Open Label First-in-Human Study With ABBV-CLS-579 Alone and in Combination in Subjects With Locally Advanced or Metastatic Tumors.’ The study aimed to evaluate the safety and efficacy of the investigational drug ABBV-CLS-579, both as a monotherapy and in combination with other agents, for treating advanced solid tumors. This study is significant as it seeks to establish a safe and effective dosage for ABBV-CLS-579, potentially offering new treatment options for patients with difficult-to-treat cancers.
The study tested ABBV-CLS-579, an oral capsule, alone and in combination with a PD-1 inhibitor (IV infusion) and a VEGFR TKI (oral tablet). These interventions target advanced solid tumors, including head and neck squamous cell carcinoma, non-small cell lung cancer, and clear cell renal cell carcinoma.
The study was interventional, non-randomized, and followed a sequential model with no masking. Its primary purpose was treatment-focused, aiming to determine the drug’s safety and efficacy in escalating doses.
The study began on June 3, 2020, and its primary completion was recently updated on September 24, 2025. These dates mark the study’s progress and its recent completion, providing crucial data for further analysis and potential future studies.
This update could influence AbbVie’s stock performance positively, as successful results may enhance investor confidence and position the company favorably against competitors in the oncology market. The collaboration with Calico Life Sciences LLC also highlights industry interest in innovative cancer treatments.
The study is now completed, with further details available on the ClinicalTrials portal.